According to GlobalData’s company profile on Cidara Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Cidara Therapeutics‘s grant share as of January 2024 was 27%. Grant share is based on the ratio of number of grants to total number of patents.
Conjugates for treating viral infections
A recently granted patent (Publication Number: US11833213B2) discloses a novel conjugate described by a specific formula (D-I). The conjugate, as per the claims, involves the attachment of L to the nitrogen atom of a surface exposed lysine of E or the sulfur atom of a surface exposed cysteine of E. Additionally, the patent mentions the dimerization of two Es to form an Fc domain when n is 2, and T being an integer from 1 to 10 in certain instances.
Furthermore, the patent claims cover a population of conjugates where the average value of T falls within the range of 1 to 5. Each E in the conjugate is specified to comprise amino acid sequences of SEQ ID NO: 63, 64, 67, or 68. These claims highlight the specific structural and compositional features of the conjugate, providing a basis for potential applications in various fields requiring such molecular configurations.
To know more about GlobalData’s detailed insights on Cidara Therapeutics, buy the report here.
From 
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies